medulloblastoma - search results
If you're not happy with the results, please do another search
Inhibiting DHODH in medulloblastoma of the MYC-amplified subtype stopped cancer growth but did not interfere with surrounding normal neural stem cells.
This research is reportedly the first to create a new workflow for neoantigen identification that incorporates both genetic sequencing and protein identification to create a personalized treatment for medulloblastoma in children.
Researchers have discovered a protein biomarker for the childhood brain cancer medulloblastoma that can help predict which patients will have a worse outcome, or not respond to chemotherapy.
The researchers developed a test to detect MRD, and thus the risk of relapse, earlier than a recurrent tumor would be identified using traditional imaging technologies such as magnetic resonance imaging (MRI) and computerized tomography (CT) scans.
Researchers have identified a network of protein-protein interactions implicated in promoting aggressive medulloblastoma. From that information, the team was able to pair drugs with a particular mechanism of action to gene expression data derived from medulloblastoma patients.
The research showed that an enzyme called GABA transaminase, abbreviated as ABAT, aids metastases in surviving around the brain and spinal cord and in resisting treatment.
Preclinical research in human tissue samples, human cell lines, and mice demonstrates a new strategy of starving tumor cells of energy to prevent further growth, which could potentially lead to changes in how some patients with medulloblastoma are treated in the future.
The research suggests the nature and outcome of medulloblastoma relapse are biology and therapy dependent, providing translational opportunities for improved disease management through ongoing surveillance, prognostication, and risk-stratified selection of second-line treatments.
The researchers discovered several drugs stopped growth of cells from the most aggressive medulloblastoma subtype: actinomycin D, oleandrin, gambogic acid, idarubicin, and bortezomib. In a study of live mice with the patient-derived xenograft cells, actinomycin D extended their survival.
Tumor DNA from the brain cancer medulloblastoma is present in large quantities in the cerebrospinal fluid and can be used to accurately diagnose and monitor disease progression, show Spanish study findings.